Combined immune checkpoint blocking (CICB) therapy targeting CTLA-4 and PD-1 is associated with high clinical benefits across tumor types, but unfortunately, the incidence of irAEs is also higher with the widespread use of CICB. The gene discussed is CTLA4; the disease is neoplasm.